Corvus Pharma Stock (NASDAQ: CRVS) stock price, news, charts, stock research, profile.
Open | $2.050 |
Close | $2.080 |
Volume / Avg. | 307.162K / 253.843K |
Day Range | 1.910 - 2.170 |
52 Wk Range | 1.050 - 4.190 |
Market Cap | $130.107M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 65 |
Short Interest | 2.71% |
Days to Cover | 7.52 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Corvus Pharma (NASDAQ: CRVS) through any online brokerage.
Other companies in Corvus Pharma’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Molecular Partners (NASDAQ:MOLN), CytomX Therapeutics (NASDAQ:CTMX), Cellectar Biosciences (NASDAQ:CLRB) and FibroGen (NASDAQ:FGEN).
The latest price target for Corvus Pharma (NASDAQ: CRVS) was reported by Oppenheimer on Tuesday, May 7, 2024. The analyst firm set a price target for 8.00 expecting CRVS to rise to within 12 months (a possible 284.62% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Corvus Pharma (NASDAQ: CRVS) is $2.08 last updated May 10, 2024 at 5:58 PM EDT.
There are no upcoming dividends for Corvus Pharma.
Corvus Pharma’s Q2 earnings are confirmed for Tuesday, August 6, 2024.
There is no upcoming split for Corvus Pharma.
Corvus Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.